CROSSJECT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.21 EUR | -0.90% |
|
+7.02% | -55.53% |
| May. 03 | Crossject: praised for extended agreement on Zepizure | CF |
| May. 02 | Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 | 12.83M 13.8M | Sales 2024 * | 3.7M 3.98M | Capitalization | 84.8M 91.26M |
|---|---|---|---|---|---|
| Net income 2023 | -8M -8.61M | Net income 2024 * | -15M -16.14M | EV / Sales 2023 | 14.7 x |
| Net Debt 2023 * | 25.8M 27.77M | Net Debt 2024 * | 27.8M 29.92M | EV / Sales 2024 * | 30.4 x |
| P/E ratio 2023 * |
-3.91
x | P/E ratio 2024 * |
-5.58
x | Employees | 110 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.48% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +12.63% | ||
| 1 week | +10.40% | ||
| Current month | +8.78% | ||
| 1 month | +1.36% | ||
| 3 months | -55.40% | ||
| 6 months | -46.65% | ||
| Current year | -55.13% |
1 week
1.90
2.28
1 month
1.832.29
Current year
1.835.96
1 year
1.835.96
3 years
1.415.96
5 years
1.045.96
10 years
1.0211.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-08-07 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 15-12-31 |
| Corporate Officer/Principal | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 23-06-06 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 2.21 | -0.90% | 84 451 |
| 24-05-03 | 2.23 | +12.63% | 162,048 |
| 24-05-02 | 1.98 | -3.41% | 117,198 |
| 24-04-30 | 2.05 | -0.73% | 66,899 |
| 24-04-29 | 2.065 | +2.23% | 66,856 |
Real-time Euronext Paris, May 03, 2024 at 11:35 am EDT
More quotes
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.23
EUR
Average target price
5
EUR
Spread / Average Target
+124.22%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -55.13% | 91.35M | |
| -1.99% | 209M |
- Stock Market
- Equities
- ALCJ Stock